Shanghai Jingbo Enterprise Development Center (Limited Partnership) and Ningbo Free Trade Zone Chuangtu Investment Partnership Enterprise (Limited Partnership) agreed to acquire 2% stake in Shanghai Cell Therapy Group Co., Ltd. from Shanghai Yaoji Technology Co., Ltd. (SZSE:002605) for CNY 110 million on February 26, 2021. Within 3 working days after the agreement effectivity, the buyers will pay 50% of the price, that is CNY 55 million. Within three working days from the first day after the target’s shareholders’ meeting deliberated and approved matters related to the equity transfer, the buyers will pay 50% of the transfer price, that is CNY 55 million. Shanghai Jingbo Enterprise Development Center (Limited Partnership) will acquire 0.25% stake for CNY 15 million and Ningbo Free Trade Zone Chuangtu Investment Partnership Enterprise (Limited Partnership) will acquire 1.7% stake for CNY 95 million. Post acquisition After, Shanghai Yaoji Technology Co., Ltd. (SZSE:002605) stake in Shanghai Cell Therapy Group Co., Ltd. will decrease from 14.2119% to 12.2119%. For the Year ended December 31, 2020, Shanghai Cell Therapy Group Co., Ltd reported Total assets of CNY 1.84 billion, net assets of CNY 1.13 billion, Revenue of CNY 374 million, net loss of CNY 80.2 million. For the period January 31, 2021, Shanghai Cell Therapy Group Co., Ltd reported Total assets of CNY 1.8 billion, net assets of CNY 1.63 billion, Revenue of CNY 25.7 million, net loss of CNY 21 million. On February 26, 2021, the 17th session of the company’s 5th directorate approved the transaction.